Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: Single-centre experience in 145 patients

Annals of Oncology

Volumn 11, Issue 12, 2000, Pages 1563-1570

  Van Riel, J M G H ^a   Van Groeningen, C J ^a   Albers, S H M ^a   Cazemier, M ^a   Meijer, S ^a   Bleichrodt, R ^a   Van Den Berg, F G ^a   Pinedo, H M ^a   Giaccone, G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 fluorouracil; Arterial access device; Chemotherapy; Colorectal cancer; Hepatic arterial chemotherapy; Liver metastases; Port a cath

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CATHETER; COLORECTAL CANCER; CONTINUOUS INFUSION; DEVICE; EXPERIENCE; FEMALE; HEPATIC ARTERY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR LOCALIZATION; VASCULAR ACCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; THROMBOSIS; TREATMENT OUTCOME;

EID: 0034485967     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008369520179     Document Type: Article

References (35)

1. Factors influencing the natural history of colorectal liver metastases
2. Liver resection for colorectal metastases
3. A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil
4. Intra-arterial infusion of anticancer drugs: Theoretic aspects of drug delivery and review of responses
5. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma
6. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial
7. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases
8. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group Trial
9. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases
10. Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer
11. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature
12. Reappraisal of hepatic infusion in the treatment of liver metases from colorectal cancer
13. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
14. Results of the Intergroup (Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG) prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection for colorectal liver metastases
15. Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases
16. Intraarterial infusion (HAI) of floxuridine (FUDR) as second-line therapy of liver metastases from colorectal cancer: A GISCAD phase II study
17. Randomized trial of hepatic arterial floxuridine, mitomycin and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer
18. Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion
19. Regional chemotherapy devices: Effect of experience and anatomy on complications
20. Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy
21. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma
22. Prognostic factors for survival and disease-free survival in hepatic metastases from colorectal cancer treated by resection
23. Prospective randomized controlled trial of hepatic arterial embolisation or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases
24. Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial
25. Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intra-arterial versus continuous intra-arterial/intravenous therapy). Results of a controlled clinical trial
26. A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases
27. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil
28. Effect of regional and systemic fluorinated pyrimidines chemotherapy on quality of life in colorectal liver metastasis patients
29. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
30. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
31. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour infusion in pretreated metastatic colorectal cancer
32. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
33. Hepatic arterial infusion chemotherapy using percutaneous catheter placement with an implantable port: Assessment of factors affecting patency of the hepatic artery
34. Percutaneously implantable catheter-port system for chemotherapeutic infusion through the hepatic artery
35. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases